Shire (NASDAQ:SHPG)(NASDAQ:SHPG)(NASDAQ:SHPG) is one of the globe's biggest drug companies. It's a major player in ADHD and rare disease, and the company has been rumored as a takeover target by Allergan, and recently AbbVie (NYSE:ABBV) announced its third attempt to buy the company.
Shire's focus to date has remained squarely on growth, rather than dividends; however, the company has a solid track record of double-digit dividend payout increases over the past decade.
Given that Shire has already lost patent protection for its ADHD drug Adderall and will lose patent protection on another important ADHD drug later this year, investors are right to wonder if that dividend streak can continue.
In the following slideshow you'll learn whether I think Shire's dividend is safe and see how Shire's dividend matches up to suitor AbbVie and industry peer Novartis (NYSE:NVS).
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.